Eli Lilly & Co

This advisory (non-binding) say-on-pay proposal asks shareholders to approve the compensation disclosed for the company’s named executive officers. Management seeks shareholder endorsement to validate its executive pay philosophy — which emphasizes linking pay to company performance via a mix of annual bonuses and long-term equity awards (SVAs and RVAs) — and to reinforce alignment with shareholder value. The board and the Talent and Compensation Committee describe extensive governance practices surrounding pay-setting: use of an independent pay consultant, independent committee oversight, robust stock ownership and retention guidelines, clawback policies, and multi-year performance-based awards. The company highlights strong 2025 results (revenue, EPS, TSR) and correspondingly above-target incentive payouts as evidence the programs delivered. Because the vote is advisory, management will not be legally bound by the outcome, but it commits to consider shareholder feedback when making future compensation decisions. Key contextual factors include Lilly’s substantial use of performance-based equity, recent improvements to executive compensation practices, and a history of strong shareholder support for say-on-pay (over 94% support in recent years). A vote FOR is recommended by the board as an affirmation of current compensation design and outcomes; a vote AGAINST would signal shareholder concern about pay levels, metrics, or governance and could prompt future committee engagement and program adjustments. Investors evaluating the proposal should weigh the alignment features and governance safeguards against the absolute magnitude of CEO and NEO pay and recent payout outcomes in light of company performance and strategic investments.

This management proposal requests shareholder approval to amend the articles of incorporation to eliminate the board’s three-classified structure so that all directors would be elected annually. Management frames the change as responsive to investor feedback favoring greater accountability and the ability for shareholders to vote on all directors each year, while acknowledging prior votes and the high 80% threshold required under current charter provisions. The board also weighed countervailing benefits of classification — continuity, institutional knowledge on the board, and a measure of protection against opportunistic takeovers — but concluded that removing the classification better serves shareholder governance expectations. If adopted, the amendment would be effective after the meeting and through filings with Indiana, with incumbent directors finishing their current terms and full annual elections phased in by 2029. The board recommends FOR, arguing that other charter and bylaw safeguards and Indiana law provide reasonable protections even without classification. The proposal is notable because it again seeks a supermajority approval (80%) historically unmet; this high threshold makes passage uncertain despite recent majority support. Institutional investors should evaluate whether annual elections improve accountability in Lilly’s specific context (combined chair/CEO with a strong lead independent director, independent committees, and existing governance practices) versus the loss of continuity benefits that the board highlights. Passage would align Lilly with many governance best practices favored by activists and governance advisers; failure to pass would leave the status quo in place.

Management asks shareholders to approve charter amendments removing multiple 80% supermajority vote requirements that currently apply to fundamental corporate actions (e.g., declassification, director removal, related-person transactions, and amending those voting thresholds). The board argues removal promotes accountability and aligns governance with shareholder expectations, pointing to prior favorable majority votes and other governance safeguards like bylaws and Indiana law. Conversely, the board acknowledges supermajority provisions can protect shareholders by preventing opportunistic actions by a small group of large holders; it has weighed that tradeoff before deciding to resubmit the proposal. Passage requires an 80% vote under the charter, making adoption difficult even if a large majority supports it. From an investor perspective, the change would reduce charter-level defenses against certain transactions and increase the reliance on board fiduciary duties and statutory protections; proponents would say it improves responsiveness and reduces entrenchment risk. The board recommends FOR, emphasizing shareholder confidence and responsiveness; the high approval threshold and recurring prior attempts underscore potential governance friction between long-tenured charter protections and evolving shareholder governance norms.

The shareholder proposal (filed by Mercy Investment Services, with co-filers) demands that the board adopt a policy and amend bylaws to require an independent board chair whenever possible, phased in at the next CEO transition. The proponent argues independent chairs improve oversight and reduce conflicts inherent in a combined chair/CEO model, citing investor survey data and recent litigation and regulatory scrutiny involving Lilly as reasons the board should increase structural independence. Management counters that mandating an independent chair would remove board flexibility to choose optimal leadership for the company’s circumstances, notes that Lilly’s structure aligns with U.S. pharma peers, highlights a robust lead independent director role and independent committees, and points to past shareholder votes rejecting similar mandates. The controversy centers on tradeoffs between independent oversight and board continuity/insight from a combined chair/CEO, particularly at a science-driven company undergoing rapid product launches and regulatory attention. For a sophisticated investor analysis, consider board effectiveness metrics, the lead independent director’s authority and performance, the board’s responsiveness to shareholder engagement to date, and Lilly’s specific regulatory and litigation risk profile. Passage would change Lilly’s governance structure and potentially affect CEO-board dynamics; defeat preserves current flexibility but may leave some investors seeking other accountability mechanisms. The board recommends voting AGAINST; shareholders weighing the proposal should assess whether structural change is necessary given existing governance safeguards and recent shareholder engagement history.

The CommonSpirit Health shareholder proposal requests an annual, publicly posted report disclosing Lilly’s direct and indirect lobbying payments (federal and state totals, and amounts to trade associations/social welfare groups used for lobbying). The proponents argue consolidated reporting would improve transparency and risk oversight, addressing gaps in state-level disclosure and trade association allocations. Management contends Lilly already provides comprehensive lobbying disclosures on its Public Policy Website (federal totals, state links, trade association lists with attributed lobbying percentages) and that a separate report would not materially improve investor information relative to the burden. The substance of the debate revolves around whether Lilly’s current disclosures (dispersed across filings, the company website, and public databases) are sufficiently accessible and granular for shareholders and whether incremental standardized reporting would change governance or reputational risk assessment. Investors assessing the proposal should consider Lilly’s CPA-Zicklin Index Tier 1 ranking and existing site disclosures versus the proponents’ evidence of incomplete state-level reporting and peer practices. Passage would commit Lilly to annual consolidated disclosure, aligning with certain peers and governance best-practices advocates; failure to pass maintains status quo disclosures and relies on existing transparency channels. The board recommends voting AGAINST; shareholders should weigh the marginal benefit of a consolidated report against the company’s current disclosure practices and resource implications.